A collection of content all about Gilead Sciences.

Jan 14, 2021: Building on the drugmaker’s HIV grants, this new funding is part of Gilead’s Racial Equity Community Impact Fund.

Jun 20, 2019: Biktarvy was approved by the U.S. Food and Drug Administration in February 2018. It contains an integrase inhibitor, a nucleotide reverse tran...

Oct 3, 2019: Descovy is a fixed-dose combination containing two approved HIV medications, tenofovir alafenamide (TAF) and emtricitabine.

May 21, 2019: Stribild is a single-tablet regimen HIV Medication. Stribild was approved by the FDA in August 2012.

May 21, 2019: Genvoya is a single-tablet regimen HIV medication. Genvoya was approved by the FDA in November 2015.

Feb 2, 2021: Human Rights Campaign’s Alphonso David explains how a Gilead Sciences grant will help the LGBTQ group fight HIV and promote health equity.

May 26, 2020: Envelopes were sent to people in the pharma giant’s patient assistance program for PrEP.

May 15, 2020: Gilead Sciences provides the funds through its TRANScend initiative; Destination Tomorrow in the Bronx distributes them.

Jan 7, 2021: The U.S. government and HIV drugmaker Gilead Sciences continue to fight over patents for Truvada and Descovy as PrEP.

Jul 15, 2016: Tybost is a pharmacokinetic enhancer, a drug used to boost the blood levels of select HIV medications to make them more effective.

Feb 26, 2018: Viread is a nucleotide reverse transcriptase inhibitor HIV medication. Viread was approved by the FDA in 2001.

Nov 16, 2020: The first generic Truvada is now available in the United States.

Apr 14, 2020: Groups already receiving grants from the pharma giant can apply for new funds during the coronavirus crisis.

Feb 22, 2021: GLAAD’s free virtual summit runs from February 24 to 26. Here’s how to join discussions on faith and HIV stigma in the South.

Mar 26, 2020: The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.

Jul 15, 2016: Emtriva is a nucleoside reverse transcriptase inhibitor HIV medication. Emtriva was approved by the FDA in 2003.

Apr 14, 2020: This week’s NMAC Hangout is with leaders committed to support the HIV infrastructure during and eventually after the COVID-19 outbreak.

Feb 23, 2021: With Gilead’s COMPASS Initiative funding, Wake Forest University School of Divinity inaugurates a faith coordinating center to fight HIV.

Jul 27, 2020: The results of GLAAD’s first State of HIV Stigma Study coincide with news of a $9 million Gilead grant to fight HIV in the South.